Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology 🧪. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) 📚. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. 🎓🔬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine 🏥. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant 📖. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies 🔬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) 🏥. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine 🔬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology 📚.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate 📚, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers 🔬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors 🏅. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology 🧠💊, medicinal chemistry ⚗️, and molecular neuroscience 🔬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems 🚀, enantiomeric drug behavior 🔄, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.

Publication Top Notes

Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers

Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif

Synthesis and Properties of a Water-Soluble Ureide Derived from Gаlodif and Succinic Acid

A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers

Effect of original anticonvulsant ortho-fluoro-benzonal on immune cells functional properties at chronic ethanol intoxication

The original anticonvulsant meta-Cl-benzhydrylurea (m-CL-BHM) induces of the liver monooxygenase system and stimulates the neuroimmune response in behavioral disorders of alcoholic origin

EMBRIOGENESIS OF NEURONAL ELENENTS (GLIOBLASTS AND GABAA RECEPTORS) IN THE HUMAN BRAIN NEUROIMMUNE SYSTEM UNDER PRENATAL ALCOHOL EXPOSURE

An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism

Nazia chaudhary | Drug Repurposing | Young Scientist Award

Dr Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia Chaudhary is a distinguished cancer researcher 🧬 with a Ph.D. focused on pathways promoting tumorigenesis and therapy resistance upon Plakophilin 3 loss 🎗️. Her academic journey includes notable projects on protease-producing thermophiles 🌡️ and mitochondrial function ⚡. She co-holds patents on Lipocalin-2 antibodies 🧪 and has published extensively in high-impact journals 📚, including Redox Biology and FEBS Letters. A DST Inspire Faculty Fellow (2023) 🌟, she has received numerous awards, including the Vaishno Endowment Prize 🏆 and Mahindra Talent Scholarships 🎓. Dr. Chaudhary’s impactful work has been presented globally 🌍, including at Cold Spring Harbor Laboratory, New York.

Academic Project

Dr. Nazia Chaudhary is an accomplished researcher with a Ph.D. focused on the project “Characterization of pathways that promote tumorigenesis, radio, and chemo-resistance upon Plakophilin 3 loss.” 💡🧬 She worked on isolating and characterizing protease and antimicrobial-producing thermophiles from Ganeshpuri hot springs at St. Xavier’s College, Mumbai (Jan-Apr 2015). 🌋🔬 Additionally, she contributed to the external project “MKT1 Dependent Regulation of Mitochondrial Function” at Tata Institute of Fundamental Research (May-Aug 2014). 🧪⚙️ Her EXSP project involved isolating and screening thermophilic Actinomycetes for enzymes with industrial importance. 🔍🌡️ Dr. Chaudhary’s diverse research showcases her expertise in microbiology and biotechnology. 🌟

Conference Attended

Dr. Nazia Chaudhary has showcased her research on various esteemed platforms. She presented a poster titled “Screening of Thermophilic Actinomycetes Capable of Producing Enzymes of Industrial Importance” at the Shri Sajjan Gupta Memorial Trophy for Excellence in Biological Science, held on December 11, 2012, at G.N. Khalsa College. Another poster, “Increase in Lipocalin2 Expression Upon Plakophilin3 Loss Confers Chemo and Radioresistance to Tumor Cells,” was presented at the Environmental Mutagen Society of India (EMSI) conference in January 2018 at BARC, Mumbai, and at the prestigious Mechanisms & Models of Cancer meeting in August 2018 at Cold Spring Harbor Laboratory, New York. 🌟🔬📊

Awards and Honors

Dr. Nazia Chaudhary is a distinguished scholar with multiple accolades. She was awarded the prestigious DST Inspire Faculty Award in 2023 and recognized for her research on lipocalin 2 expression and chemo-radiotherapy resistance at the 14th Indo-Australian Biotechnology Conference. She served as a Board of Studies member for Sophia College’s Zoology Department (2018-2021). Throughout her academic journey, she earned various honors, including the Ramidevi Murlidhar Jalan Award 🏆, Saifee Education Aid Scholarship 🎓, and the Mahindra Search for Talent Scholarship 🌟. Her exceptional performance also earned her the Mrs. A. Varghese Prize 🥇 and several other prestigious scholarships and awards.

Patent

Dr. Nazia Chaudhary, along with Sorab N. Dalal, Manjula Das, Sujan K. Dhar, and Smitha P. K., contributed to the development of “Antibodies Against Lipocalin-2 and Use Thereof.” This groundbreaking research led to two key milestones. The first was the PCT application (PCT/IN2020/051068) with publication no. WO/2021/137254 on July 8, 2021. The second was the Indian patent (DBT Indian Patent no: 202021000274) granted on July 30, 2021, published in the Patent Office journal no. 31/2021. These innovations hold significant potential for medical advancements. 🧬💉🧪🔬

Research Focus

Dr. Nazia Chaudhary’s research focuses on the molecular mechanisms of cancer progression, therapy resistance, and invasion, particularly in triple-negative breast cancer (TNBC) and colorectal cancer. She investigates the role of Lipocalin 2 (LCN2) in regulating cellular processes like focal adhesion formation, actin glutathionylation, and ferroptosis inhibition, which are critical for tumor cell migration and resistance to treatment. Her work explores the interplay between signaling pathways, such as Src activation and glutathione metabolism, to uncover potential vulnerabilities in cancer cells. 🧬💥💉🧪🧫